Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) yesterday announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and migraine development programs will be presented at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia. In addition, an article in the peer-reviewed publication, US Neurology, discussing PBA diagnosis in patients with Alzheimer’s disease (AD) and other dementias, will be available at AAN and was recently published online. Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) shares after opening at $3.38 moved to $5.15 on last trade day and at the end of the day closed at $4.98. Company price to sales ratio in past twelve months was calculated as 8.86 and price to cash ratio as 17.28. Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) showed a positive weekly performance of 43.52%.
IsoRay Inc. (NYSE:ISR) yesterday announced the publication of the first major peer reviewed study showing improved results using IsoRay’s Cesium-131 seeds in the treatment of gynecologic cancer. IsoRay, Inc. (NYSEMKT:ISR) shares advanced 29.57% in last trading session and ended the day on $2.41. ISR return on equity ratio is recorded as -71.90% and its return on assets is -56.60%. IsoRay, Inc. (NYSEMKT:ISR) yearly performance is 372.55%.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a specialty pharmaceutical company, yesterday presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson’s disease treatment. The data, from Adamas’ Phase 2/3 EASED study, included assessments of patients receiving ADS-5102 using a metric called the Clinician’s Global Impression of Change (CGI-C). Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) shares moved up 15.31% in last trading session and was closed at $18.45, while trading in range of $16.00 – $19.11. Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) year to date (YTD) performance is 31.69%.
22nd Century Group (NASDAQ:XXII) VP Michael Robert Moynihan sold 100,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $2.44, for a total value of $244,000.00. Following the transaction, the vice president now directly owns 1,038,934 shares in the company, valued at approximately $2,534,999. 22nd Century Group Inc. (NYSEMKT:XXII) weekly performance is 13.56%. On last trading day company shares ended up $2.68. 22nd Century Group Inc. (NYSEMKT:XXII) distance from 50-day simple moving average (SMA50) is -25.08%. Analysts mean target price for the company is $9.00.
Leave a Reply